GE Partners Rockwell To Build Biopharmaceutical Solutions
Zacks Investment Research | Apr 11, 2019 09:49PM ET
General Electric Company’s (NYSE:GE) business arm — GE Healthcare — has joined forces with Rockwell Automation, Inc. (NYSE:ROK) to make manufacturing process more flexible and scalable for biopharmaceutical companies.
The collaboration will leverage GE Healthcare’s proficiency in bio-pharmaceutical manufacturing technologies along with Rockwell’s industry-leading expertise in automation. Their collective proficiency in single-use bioprocessing, automation and IT knowledge will enable biopharmaceutical companies to boost manufacturing competencies, quickly respond to market demand and deliver advanced solutions.
Notably, both the companies will work on integrating the FlexFactory single-use equipment with Figurate bioprocess automation. This will help firms improve reproducibility, repeatability and compliance, thus enhancing their operational efficiency. The solutions will also facilitate digitization of batch files and processes, which will significantly shorten review times for companies. Additionally, these will enable customers in delivering instructions to workers with augmented reality, eventually enhancing batch execution, equipment setup, operations and training.
Separately, GE Healthcare also joined the Rockwell Automation PartnerNetwork Program as an equipment manufacturer partner. The move will allow it to work in collaboration with a group of companies in offering state-of-the-art distributed control systems required for streamlining customers’ supply chain and simplifying project implementation.
Existing Business Scenario
General Electric intends to become more competent by focusing on core businesses. In June 2018, the company announced its plan to become a high-tech industrial company focused on Aviation, Power and Renewable Energy. However, a weakening Power business remains a key cause of concern.
Notably, the Zacks Rank #3 (Hold) company’s share price has increased 20.5% on a year-to-date basis compared with 22.1% growth recorded by the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.